Dominating India’s pharmaceutical charts, Eli Lilly’s Mounjaro has claimed the title of the country’s highest-selling medicine by value, clocking ₹100 crore in sales during October, according to a Reuters report. The milestone reflects India’s surging demand for modern metabolic treatments, particularly those addressing diabetes and obesity, two of the nation’s fastest-growing health concerns.

Launched in March 2025, Mounjaro has quickly established itself as a market leader among prescription drugs. Data from research firm Pharmarack shows that by the end of October, the product had already generated ₹333 crore in total revenue, outpacing competitors by a considerable margin. In terms of volume, its usage was reportedly ten times higher than Novo Nordisk’s Wegovy, which entered the India

See Full Page